Shanghai Haohai Biological Technology Co., Ltd. provided consolidated earnings guidance for the six months ended June 30, 2015. For the period, the company expects that the Group would record the following increases in its unaudited revenue and consolidated profit attributable to the equity holders of the company, an increase of over 30% in revenue for the six-month period ended 30 June 2015 as compared to the group's revenue for the corresponding period in 2014; and an increase of over 70% in unaudited consolidated profit attributable to equity holders of the company for the six-month period ended 30 June 2015 as compared to the Group's profit attributable to the equity holders of the company for the corresponding period in 2014; and after excluding one-off realized foreign exchange gain from the proceeds of the company's listing in April 2015, an increase of over 40% in unaudited consolidated profit attributable to equity holders of the company for the six-month period ended 30 June 2015 as compared to the Group's profit attributable to the equity holders of the company for the corresponding period in 2014. The increases in revenue and profit as are mainly attributable to the consistent growth in the sales of the sodium hyaluronate injection signature product of the Group, and the rapid growth in the sales of certain products of the Group launched in recent years, namely medical chitosan products for intra-articular injection and Matrifill branded dermal filler products, leading to an increase in the market share of the Group in the result.